Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.
You may also be interested in...
Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says
The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.
Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says
The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.
Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.